RESULTS	The cure and effective rates were 67.92 and 88.68 % in the biapenem group and 76.02 and 93.40 % in the imipenem/cilastatin group , the bacterial eradication rates were 93.83 and 98.82 % , and the adverse-event rates were 6.54 and 7.41 % , respectively .\